CELC
Celcuity Inc.
$131.06
+0.27%
2026-05-08
About Celcuity Inc.
Celcuity Inc., a clinical-stage biotechnology company, focuses on the development of targeted therapies for the treatment of various solid tumors in the United States. The company's lead drug candidate includes Gedatolisib, which selectively targets various Class I isoforms of phosphatidylinositol-3-kinase (PI3K) and the two mechanistic targets of rapamycin (mTOR) sub-complexes, mTORC1 and mTORC2 to treat patients with hormone receptor positive (HR+), human epidermal growth factor receptor 2 negative (HER2-) or HR+/HER2-, advanced or metastatic breast cancer (ABC), and patients with metastatic castration resistant prostate cancer (mCRPC). The company had a license agreement with Pfizer Inc. for the development and commercialization rights to Gedatolisib. Celcuity Inc. was incorporated in 2011 and is based in Minneapolis, Minnesota.
Key Fundamentals
Forward P/E
-96.90
EPS (TTM)
$-3.78
ROE
-163.8%
Profit Margin
0.0%
Debt/Equity
320.13
Price/Book
63.23
Beta
0.09
Market Cap
$6.37B
Avg Volume (10D)
1.4M
Recent Breakout Signals
Recent Price Range (60 Days)
60D High
$151.02
60D Low
$100.01
Avg Volume
775K
Latest Close
$131.06
Get breakout alerts for CELC
Sign up for Breakout Scanner to receive daily notifications when CELC triggers breakout signals. Build custom AI screeners and backtest strategies.
Start Free Trial7-day free trial. No card required.
Celcuity Inc. (CELC) is listed on the NASDAQ (NASDAQ). Breakout Scanner monitors CELC daily for breakout patterns including long-term ceiling breakouts, momentum breakouts, and near-breakout watch setups. CELC operates in the Healthcare sector within the Biotechnology industry. Data is provided for informational purposes only and does not constitute financial advice.